News

Podcast

Treating Waldenstrom’s Macroglobulinemia

Author(s):

Kristie L. Kahl

In this episode of the “CURE Talks Cancer” podcast, we spoke with Dr. Asher Chanan-Khan about current standards of care for Waldenstrom macroglobulinemia, as well as a clinical trial looking at a novel therapy.

In this episode of the “CURE Talks Cancer” podcast, we spoke with Dr. Asher Chanan-Khan about the current standards of care for Waldenstrom macroglobulinemia, also known as WM.

WM is a rare, incurable disease. Its current standards of care available consist of Rituxan (rituximab), Imbruvica (ibrutinib) combinations or monotherapy in the first- and second-line setting. However, there are no treatments currently approved for the third line.

Chanan-Khan discussed these options, as well as a novel agent, CLR 131, that is being evaluated in a phase 2 study.

For more news on cancer updates, research and education, don’t forget to subscribe to CURE®’s newsletters here.

Newsletter

Stay up to date on cancer updates, research and education

Subscribe Now!
Related Videos
Patients in rural or underserved areas may have worse outcomes, highlighting the need for early support to address care access barriers.
Image of doctor with text.
Mark Daniels, 83, credits CAR T-cell therapy and compassionate care for helping him overcome lymphoma and endure the isolating treatment toll.
Waldenstrom macroglobulinemia is often slow growing, with high survival but lower quality of life over time, explained researcher Alisha Kimble.
Illustration of doctor.
There was no evidence that CAR T directly caused secondary malignancies, despite FDA warnings, citing prior treatments as the cause, according to research.
Dr. Tycel Phillips is an Associate Professor in the Division of Lymphoma, Department of Hematology and Hematopoietic Cell Transplantation, at City of Hope in Duarte, California.
Dr. Richard “Rick" Winneker
Image of a man wearing a suit with a red bowtie.
Related Content
Image of ribbon
July 2nd 2025

This Wasn’t the Plan: My Mother and Her Silence

Ajay Shanker Mishra
In part 4, the author reflects on her mother’s silent strength and unwavering love during her cancer journey, as she cared for her daughter while silently battling her own illness.
cancer horizons logo: a white microphone on a navy blue background
March 11th 2024

Oncology Approvals, Psychological Outcomes for Survivors and an Ovarian Cancer Vaccine

Alex Biese Brielle Benyon
Last week we saw some FDA approvals come through, as well as research that explored the psychosocial outcomes of individuals who survived pediatric rhabdosarcoma.
At age 19, stage 4 blood cancer changed everything, leading to a journey of resilience and quiet hope: © stock.adobe.com.
June 28th 2025

This Wasn't the Plan: When the World Shifted After Cancer

Ajay Shanker Mishra
At age 19, I was a medical student with big dreams — until stage 4 blood cancer changed everything, leading to a journey of resilience and quiet hope.
cancer horizons podcast logo: a white microphone on a blue background
March 4th 2024

Cannabis Talks During Cancer, Cardiometabolic Comorbidities and Current Research

Alex Biese Brielle Benyon
In addition to a breakthrough therapy designation for a lung cancer drug, this week we’ll be talking a lot about additional side effects and health conditions that may come with a cancer diagnosis, and how to manage them.
Image of blood.
June 5th 2025

Iopofosine-131 Earns FDA Breakthrough for Waldenstrom Macroglobulinemia

Spencer Feldman
Iopofosine-131 received FDA breakthrough status for relapsed or refractory Waldenstrom macroglobulinemia, showing strong response rates in early trials.
Image of blood cells.
May 27th 2025

Improving Education and Advocacy in Waldenström Macroglobulinemia

Ryan Scott
Education and patient advocacy are essential to improving care in Waldenström macroglobulinemia amid clinical advances, according to Dr. Shirley D'Sa.